Contact Us marketing@medicilon.com
ABOUT
Company Profile
Corporate Culture
Management Team
Company History
Message from the CEO
Honors and Awards
SERVICES
SERVICES
01 Drug Discovery
Chemistry Research Biology Research Early Pharmacokinetics
02 Pharmaceutical Research
Intermediates Active Pharmaceutical Ingredients Pharmaceutical preparation Analytical Method Development and Quality Control CMC Filings Analytical Testing Center
03 Preclinical Research
Pharmacology & Pharmacodynamics Drug Safety Evaluation DMPK Bioanalysis IND Filings
PLATFORM
PLATFORM
01 One-stop Integrated Services
Liposome Drug Development Drug Discovery Pharmaceutical Research Preclinical Research Botanical Drug Preclinical R&D
02 Innovative Drug R&D Services
Peptide Drug Conjugate (PDC) Antibody Nucleic Acid Drug Cellular Immunotherapies mRNA Vaccine PROTAC ADC
03 Key Technical Services for Drug R&D
Cytokine and Biomarker Detection Metabolite Identification (MetID) Drug Forming Research Flow Cytometry Technology SEND Format Conversion Flow Sorting NanoString nCounter Detection Routes of Drug Administration
04 Drug Efficacy Evaluation for Common Diseases
Rodent Cerebrovascular Disease Inflammatory and Immune Diseases IO Pharmacodynamic Model
05 High-end Preparations Technology Platform
Skin Topical Preparation Ophthalmic drug Inhalation drug
06 Targeted Drugs R&D Services
STAT3-targeted Drugs R&D Service KRAS-targeted Drugs R&D Service GLP-1 New Drug R&D Service
07 Safety Assessment Lab of Process Chemistry

08 Public Services
CAREERS
Talent Development
Campus Recruitment
Recruitment
NEWS
Medicilon Events
Featured Stories
Market Events
Videos
A.C.E.
INVESTORS
Stock Information
Investment Contact
CLIENT CENTER
Intellectual Property Protection
Clients Testimonials
Downloads
Partnerships
Medicilon Support
Newsletters
CN
×
中
Close Button
Customer Center
Customer Center
Case Studies Clients Testimonials Downloads Partnerships Intellectual Property Protection Newsletters
HomeClient CenterMedicilon SupportIND 100
IND 100 Publications
Jun 30,2021
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Recently, the orphan drug KBMAB-16 (intravenous injection of tumor necrosis factor-α inhibitor), a major project of a well-known Chinese pharmaceutical company located in Chengdu, was successfully approved for clinical trial application (IND) by the US Food and Drug Administration (US FDA).
See More
[Medicilon Assist]KBMAB-16 for the Treatment of Sarcoidosis has been Approved by the FDA for Clinical Trials
Jun 08,2021
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
On June 2, 2021, the National Medical Products Administration (NMPA) officially announced that the glucocorticoid drug PA9159 nasal spray was approved for clinical use.
See More
Medicilon assists Palaatu to obtain clinical approval for Class 1 new drug PA9159 for rhinitis
Apr 21,2021
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
On April 8, 2021, the clinical trial application of HG381 for injection, developed by HitGen, was approved by National Medical Products Administration (NMPA).  HG381 for
See More
Medicilon assists HitGen's HG381 to be approved as China's first clinical STING agonist
Mar 29,2021
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Livzon Pharmaceutical Group Inc. (Livzon) obtained a "novel coronavirus recombinant protein vaccine” (V-01) clinical trial approval from the National Medical Products Administration (NMPA) (Batch No.
See More
Medicilon assists Livzon Pharmaceuticals Group to obtain the clinical approval of novel coronavirus vaccine V-01
Feb 25,2021
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
On February 22, 2021, Nanjing TransThera Biosciences Co., Ltd. ("TransThera”) and the life science company of South Korea's LG Chem ("LG Chem”) jointly announced the
See More
Medicilon assists TransThera to obtain the Chinese IND for the VAP-1 inhibitor TT-01025, which has the first human subject in the USA
Feb 08,2021
3D011-08 from 3D Medicines was approved of conducting clinical trials
Jan 29th, 2021 – CDE announced that the innovative drug, 3D011-08 from 3D Medicines, was approved of conducting clinical trials. It indicates that 3D Medicines
See More
3D011-08 from 3D Medicines was approved of conducting clinical trials
Feb 08,2021
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Jan.27, 2021 – Xuanzhu Biotech announced that their XZP-5610, a new treatment for NASH (non-alcoholic steatohepatitis), was approved of clinical trials by China NMPA. XZP-5610
See More
Xuanzhu Biotech Announced the Clinical Trial Approval of XZP-5610
Oct 31,2020
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
On October 31, 2020, ABM Therapeutics awarded the "Our First Candidate Compound" commemorative trophy to Dr. Li Zhigang, Vice President of Research and Development of Medicilon Chemistry Department, to thank Medicilon for its FTE form of cooperation, the pharmaceutical and chemical team helped it discover and advance the first drug candidate ABM-1310 to enter the clinical phase I in the United States.
See More
ABM Therapeutics presented Medicilon with a commemorative trophy of "our first candidate compound"
Jul 20,2020
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
On July 20, 2020, DAC Biotech's new ADC drug development, TROP2-ADC—DAC-002 was approved of clinical study by NMPA. for the indication of solid malignant tumor. Medicilon completed preclinical pharmacokinetic and toxicological studies in this project, accelerating the development process. DAC-002 is an ADC anti-Trop2 monoclonal antibody conjugated by an intelligent ligand against Tubulysin B analogue.Read more
See More
Medicilon assisted Hangzhou DAC Biotech in approval of clinical study of ADC drug DAC-002
Jun 04,2020
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Congratualtions to Medicilon's partner, Bio-Thera, on obtaining NMPA's approval of clinical trials of BAT1308. On May 27th, 2020, Bio-Thera Solutions, Ltd, annouced the approval of
See More
Congratualtions to Bio-Thera on obtaining NMPA’s approval of clinical trials of BAT1308
Stock Code
688202

Global

Address: 20 Maguire Road, Suite 103, Lexington, MA 02421(America)

Tel: +1(781)535-1428(U.S.)

Address: Allia Future Business Centre Kings Hedges Road Cambridge CB4 2HY, UK

Tel: 0044 7790 816 954 (Europe)

Email: marketing@medicilon.com

  

Address: 5th Floor, 62, Banpodae-ro 4-gil, Seocho-gu, Seoul, 06719 South Korea

Tel: +82 70-8269-5849

China

Address: No.585 Chuanda Road, Pudong New Area, Shanghai (Headquarters)

Postcode: 201299

Tel: +86 (21) 5859-1500 (main line)

Fax: +86 (21) 5859-6369

Facebook icon
Twitter icon
Linkedin icon
Youtube icon
© 2023 Shanghai Medicilon Inc. All rights reserved All Rights Reserved Privacy Policy
Website Map
-->